SI-BONE, Inc. (NASDAQ:SIBN) Q2 2023 Earnings Conference Call August 7, 2023 4:30 PM ET

Company Participants

Saqib Iqbal - Senior Director, FP&A and Investor Relations

Laura Francis - Chief Executive Officer

Anshul Maheshwari - Chief Financial Officer

Conference Call Participants

Craig Bijou - Bank of America

Young Li - Jeffries

Kyle Rose - Canaccord

Samuel Brodovsky - Truist Securities

Andrew Ranieri - Morgan Stanley

Operator

Good afternoon, and welcome to SI-BONE's Second Quarter Earnings Conference Call. At this time, all participants are in listen-only mode. We will be facilitating a question-and-answer session towards the end of today’s call. As a reminder, this call is being recorded for replay purposes.

I would now like to Saqib Iqbal, Senior Director of Investor Relations at SI-BONE for a few introductory comments. Sir, please go ahead.

Saqib Iqbal

Thank you for participating in today's call. Joining me are Laura Francis, Chief Executive Officer; and Anshul Maheshwari, Chief Financial Officer. Earlier today, SI-BONE released financial results for the quarter ended June 30, 2023. A copy of the press release is available on the company's website.

Before we begin, I'd like to remind you that management will make statements during this call that include forward-looking statements within the meaning of federal securities laws which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Any statements contained in this call that relate to expectations or predictions of future events, results or performance are forward-looking statements. These forward-looking statements are based on the company's current expectations and inherently involve risks and uncertainties. These risks include the impact SI-BONE’s ability to introduce and commercialize new products and indication, SI-BONE’s ability to maintain favorable reimbursement for its products and procedures, the impact of potential economic weakness, on the ability and desire of patients to undergo elected procedures, SI-BONE’s ability to manage risk to supply chain, the impact of future capital requirements driven by new product introductions and risks to the continued renormalization of the healthcare operating environment.

Other forward looking statements include are examination of operating trends, and our future financial expectations, such as expectations for surgeon training and adoption, active surgeons new products and clinical trial enrollment, and are based upon our current estimates and various assumptions.

These statements involve material risks and uncertainties that could cause actual results or events to materially differ from those anticipated or implied by these forward looking statements. Accordingly, you should not place undue reliance on these statements. For the list and description of the risks and uncertainties associated with our business. Please refer to the risk factors section of our most recent Form 10-K and form 10-Q, filed with the Securities and Exchange Commission.